Study guide

10.1 Product Selection: Generic Substitution (ORS 689.515) & Biologic Interchange (ORS 689.522)

Oregon Multistate Pharmacy Jurisprudence Examination MPJE

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Overview & Oregon Legal Framework

1.1 Oregon MPJE Format, Fees, Blueprint & 2027 Changes 1.2 Federal–Oregon Legal Hierarchy, Agencies & the Board of Pharmacy

2 Chapter 2: Pharmacist & Pharmacist-in-Charge Responsibilities

2.1 Pharmacist Responsibilities, Supervision & Prohibited Practices 2.2 Pharmacist-in-Charge: Qualifications, Duties, Inventories & Self-Inspection

3 Chapter 3: Pharmacy Technicians, Interns & Preceptors

3.1 Pharmacy Technicians (COPT & PT): Licensure, Permitted Tasks & Limits 3.2 Pharmacy Interns & Preceptors: Licensure, Scope & Supervision

4 Chapter 4: Licensure, Renewal, Discipline & Impaired Practitioners

4.1 Pharmacist Licensure by Examination, Score Transfer & Reciprocity 4.2 License Renewal, Continuing Pharmacy Education & Lapse Rules 4.3 Grounds for Discipline, Sanctions & Mandatory Reporting Deadlines 4.4 Impaired Practitioners & the Health Professionals' Services Program (HPSP)

5 Chapter 5: Prescriber Authority & Prescription Requirements

5.1 Prescriber Authority, DEA Registration & Out-of-State Prescriptions 5.2 Non-Controlled Prescriptions: Required Elements, Signatures, Expiration & Refills 5.3 Controlled Substance Prescriptions: Schedules II–V, EPCS, Emergency Orders & Oregon's CV Limit 5.4 Drug-Use Limitations & Special Prescriptions: REMS, Death with Dignity, EPT & Standing Orders 5.5 Legitimate Medical Purpose, Corresponding Responsibility & Red Flags

6 Chapter 6: Pharmacist Clinical Services & Prescriptive Authority

6.1 CDTM, Clinical Pharmacy Agreements, MTM & Laboratory Testing 6.2 Pharmacist Prescribing: Statewide Protocols, the Formulary & General Requirements 6.3 Pharmacist Prescribing of Hormonal Contraception (ORS 689.689) 6.4 Tobacco Cessation Protocol: Training, Screening, NRT & Non-NRT Prescribing 6.5 Vaccine Prescribing & Administration: Age Floors, Protocols, Training & ALERT IIS 6.6 Opioid Overdose Reversal & MOUD: Naloxone Prescribing, Standing Orders, Immunity & Buprenorphine

7 Chapter 7: Counseling, Language Access & Confidentiality

7.1 Patient Counseling: Triggers, Who May Offer or Accept a Refusal & Documentation 7.2 Language Access & Accessibility: Dual-Language Labels, Registry Interpreters & Prescription Readers 7.3 Patient Confidentiality: Oregon Rules, HIPAA, Part 2 & PDMP Privacy

8 Chapter 8: The Dispensing Process

8.1 Prospective Drug Utilization Review: Oregon's Eight Categories, Documentation & Who May Perform It 8.2 Oregon PDMP: Reporting Within 72 Hours, Covered Drugs, Access & Confidentiality 8.3 Prescription Transfers: Oregon's Next-Business-Day Duty & Federal Controlled Substance Limits 8.4 Dispensing Exceptions: 72-Hour Emergency Refills, Continuation of Therapy, Insulin & Declared Emergencies 8.5 Partial Fills: Schedule II (72-Hour, 30-Day CARA & 60-Day LTCF/Terminal) and Schedules III–V 8.6 Prescription Labeling: Oregon Elements, Physical Description, Expiration Dating & Med Paks 8.7 Packaging: PPPA Child-Resistant Containers, Waivers, Exemptions & Oregon's New-Container Rule 8.8 Conditions Prohibiting Dispensing, Quarantine, Returned Drugs & Charitable Reuse

9 Chapter 9: Nonprescription & Restricted Products

9.1 Nonprescription Drugs: Outlet Registration, Drug Facts Labeling & OTC Packaging 9.2 Dispensing-Restricted Nonprescription Products: Pseudoephedrine, Exempt Schedule V & Others

10 Chapter 10: Product Selection: Generic & Biologic Substitution

10.1 Product Selection: Generic Substitution (ORS 689.515) & Biologic Interchange (ORS 689.522)

11 Chapter 11: Acquisition, Records, Inventories & Loss Reporting

11.1 Ordering & Acquiring Controlled Substances: DEA Registration, Form 222, CSOS & the 5% Rule 11.2 Distribution Records, DSCSA, Recalls & Oregon Record Retention 11.3 Controlled Substance Inventories: Oregon's 367-Day, 93-Day, 31-Day & 15-Day Rules 11.4 Theft & Loss Reporting, Disposal, Reverse Distribution & Take-Back Receptacles

12 Chapter 12: Pharmacy Operations, Storage, Security & Special Practice Settings

12.1 Pharmacy Operations: Pharmacist Presence, Policies, Equipment, Signage, Hours & Closures 12.2 Drug Storage & Cold Chain: Temperatures, Monitoring Plans, Excursions & Vaccine Units 12.3 Security & Non-Pharmacist Access: Keys, Double Set-Ups, Institutional Night Access & DEA Controls 12.4 Hazardous Drugs: NIOSH 2024 List, USP 800 Controls, Assessment of Risk & Disposal 12.5 Compounding: OAR 855-183 (June 2026), USP 795/797/800, 503A vs. 503B & Beyond-Use Dates 12.6 Delivery of Drugs: Depots, Mail Delivery, Prescription Lockers, Kiosks & Mobile Pharmacies 12.7 Central Fill, Remote Processing, Telework & Remote Dispensing Site Pharmacies

13 Chapter 13: Drug Outlet Registration, Inspection & Institutional Practice

13.1 Drug Outlet Classes, Registration, Changes of Ownership/Location/Name & Non-Resident Pharmacies 13.2 Inspections, Self-Inspection Forms & Discipline of Drug Outlets 13.3 Institutional & Long-Term Care Practice: Drug Rooms, Night Access, E-Kits, ADCs & ED Prepacks

10.1 Product Selection: Generic Substitution (ORS 689.515) & Biologic Interchange (ORS 689.522)

Key Takeaways Explain This Topic AI

Under ORS 689.515, an Oregon pharmacist may substitute a therapeutically equivalent drug with the same generic name, strength, quantity, dose and dosage form, but only if it saves the purchaser money or costs the same.

When the prescriber is not reasonably available, an Oregon pharmacist may switch between oral tablet, capsule and liquid forms, except for unique delivery systems.

Oregon pharmacies must post a counter sign, in letters at least one inch high, saying a less expensive therapeutically equivalent drug may be substituted unless the patient objects.

Oregon prescribers block substitution with notations such as 'No substitution', 'N.S.', 'Brand medically necessary' or 'D.A.W.'; e-prescriptions also need electronic indicators, and none may be a default value.

Under ORS 689.522, an Oregon pharmacist may substitute only FDA-designated interchangeable biologics, if not prohibited, and must inform the patient and keep a 3-year record, with no prescriber-notice deadline.

Last updated: October 2026

Why this matters

Area 4.4 covers "conditions for permitted or mandated product selection." Oregon's generic substitution statute ( ORS 689.515 ) and biologic interchange statute ( ORS 689.522 ) have features that differ from many states: a mandatory sign , a no-cost-increase condition, a dosage-form substitution option, and an exception for out-of-state prescriptions . Older materials often misstate the biologic rules.

  • Generic substitution (ORS 689.515)
  • When a pharmacist may substitute

Unless the purchaser instructs otherwise , and subject to the prescriber's instructions and the cost rule, a pharmacist may substitute:

A drug product with the same generic name, strength, quantity, dose and dosage form that is, in the pharmacist's professional opinion, therapeutically equivalent (ORS 689.515(2)(a)). Therapeutically equivalent means FDA-approved for interstate distribution and determined by FDA to have essentially the same efficacy and toxicity at the same dosage regimen. In practice this means an "A"-rated product in FDA's Orange Book.

When the prescriber is not reasonably available and the drug does not use a unique delivery-system technology , an oral tablet, capsule or liquid form of the prescribed drug with the same strength, dose and schedule that is therapeutically equivalent (ORS 689.515(2)(b)). Oregon's statute expressly allows this kind of dosage-form substitution .

Limits on substitution

Prescriber prohibition: the prescriber may specify in writing, by telephone or electronically that there may be no substitution (ORS 689.515(3)). Under OAR 855-041-1105(5), acceptable notations on written or oral orders are:

  • "No substitution."
  • "N.S."
  • "Brand medically necessary."
  • "Brand necessary."
  • "Medically necessary."
  • "D.A.W."

Words with similar meaning.

An electronic prescription must carry the text "brand medically necessary," or similar words, plus the matching electronic indicators. These instructions may not be default values on the prescription.

Cost: substitution is allowed only when there will be a savings in, or no increase in, cost to the purchaser (ORS 689.515(5)).

Purchaser's choice: the patient may decline substitution.

Out-of-state prescriptions: generic substitution does not apply unless the prescription authorizes it (ORS 689.525(3)).

Duties when substituting or dispensing generically

Duty Rule

Sign Post a sign, easily seen at the counter where prescriptions are dispensed, reading: "This pharmacy may be able to substitute a less expensive drug which is therapeutically equivalent to the one prescribed by your doctor unless you do not approve." Letters must be at least one inch high. If the purchaser cannot read or understand the sign, the pharmacist explains it (ORS 689.515(4); OAR 855-041-1035)

Generic-name prescriptions Dispense the lowest retail cost, effective brand in stock , consistent with professional judgment (ORS 689.515(6))

Label Name of the drug dispensed . If it has no brand name, the generic name and manufacturer (ORS 689.515(7))

Record Record the brand dispensed, or the generic name and manufacturer, for any substituted drug, and keep it 3 years (ORS 689.508)

Penalty A violation of ORS 689.515 can bring a civil penalty of up to $250 per violation (ORS 689.854), on top of other discipline

A substitution made within reasonable and prudent practice, or using a drug in a recognized formulary or government list, is not evidence of negligence . Substitution is not the practice of medicine (ORS 689.515(9)–(10)).

Reading the Orange Book

"A" codes are therapeutically equivalent. AB means bioequivalence issues were resolved with studies. AA , AN , AO , AP and AT are for conventional forms, aerosols, injectable oils, injectable aqueous solutions and topicals.

"B" codes are not considered therapeutically equivalent. Don't substitute them under ORS 689.515.

Multiple reference drugs carry numbered codes (AB1, AB2, AB3...). A generic is substitutable only for a reference product with the same code . Levothyroxine and extended-release products are classic examples. Some generics carry more than one code, so check the specific listing.

Biologic interchange (ORS 689.522)

A pharmacy or pharmacist may substitute a biological product for the prescribed biological product only if :

FDA has determined the substitute is interchangeable with the prescribed product, as shown in the Purple Book .

The prescriber has not designated that substitution is prohibited.

The patient is informed of the substitution in a manner reasonable under the circumstances.

The pharmacy or pharmacist keeps a record of the substitution for at least three years .

The Board keeps a link to FDA's list of interchangeable products. Oregon's current statute does not require the pharmacist to notify the prescriber within a set number of days after substituting. Some states and older Oregon materials describe such a notification. A biosimilar that FDA has not designated interchangeable may not be substituted. It may be dispensed only if prescribed. Insurers may still require prior authorization for any biologic (ORS 689.524).

Important

The four Oregon biologic conditions are interchangeable designation , no prescriber prohibition , patient informed and 3-year record . A "3-business-day prescriber notice" answer choice is a distractor under the current ORS 689.522.

Exam scenario

Three prescriptions arrive:

"Lipitor 40 mg #30" from an Oregon physician , no DAW. The pharmacy stocks AB-rated atorvastatin that costs the patient less. The pharmacist may substitute, label "atorvastatin 40 mg" with the manufacturer , and record it. The 1-inch sign must be posted.

The same prescription from an Idaho physician. Under ORS 689.525(3), substitution requires authorization on the prescription . Without it, dispense Lipitor or contact the prescriber.

A reference insulin , with the pharmacy stocking an FDA-designated interchangeable insulin. The pharmacist may substitute if the prescriber didn't prohibit it, tells the patient , and keeps the record 3 years .